Category Archives: Strategy

Chats Not Charts: Three Steps to Pharma Post-Marketing

by Andrew Spong (originally published on stwem.com) The air of despondency that is descending over the pharmaceutical industry’s use of social media is perverse. It has nothing to do with a putative (and also fictive) absence of interest on the patient’s part in connecting with the pharmaceutical industry. It has everything to do with the […]
Also posted in Advertising, E-Media, Guest Blog, leadership, Marketing, Patient Communication, patient education, social media | Leave a comment

Pharma Marketers: Avoid the Tactical Scrum

by Al Topin With the introduction of every new technology, tactic, or gimmick comes what I call a tactical scrum. It’s like watching young kids play their first game of T-ball or soccer. No matter how much instruction the coach gives on field position or game play, the second that ball is hit or kicked, […]
Also posted in Advertising, Agency Insight, E-Media, Guest Blog, Marketing, People, Sales, social media, Technology | Tagged , , , | Leave a comment

Baxter Splits Biopharm and Medical Products into Two Businesses

Baxter International plans to create two separate, independent global healthcare companies, with one focused on biopharmaceuticals and the other on medical products.
Also posted in Biotech | Tagged , , | Leave a comment

Allergy Shots in a Pill?

Allergy season’s dank fecundity might be welcomed in many parts of America this year. Anything that’s warmer. But the worst allergy sufferers might soon be headed back to the doctor’s office for another round of allergy shots. Or perhaps not. ALK-Abelló, a Denmark-based specialty pharmaceuticals company focused solely on allergy immunotherapy products, expects FDA to […]
Also posted in Biotech, Europe, FDA, R&D, Regulatory, Technology | Tagged , , , , , , , , , | Leave a comment

FDA, Sponsors Seek Study Endpoints Earlier in Development

As payers demand more evidence documenting medical product value, biopharma companies are responding by moving sooner to decide key clinical outcomes to measure. While clinical trials still have to document product safety, efficacy and quality, sponsors also look to demonstrate suitability for formulary placement and reimbursement. Food and Drug Administration officials support these strategies to […]
Also posted in FDA, Marketing, R&D, Regulatory | Tagged , , , , | 1 Comment
  • Categories

  • Meta